Sodium Thiosulfate to Prevent Cisplatin-Induced Hearing Loss in Pediatric Standard-Risk Hepatoblastoma


Key Points

  • Hearing loss occurred in 33% of the cisplatin-sodium thiosulfate group vs 63% of the cisplatin group.
  • The benefit was observed without jeopardizing event-free or overall survival.

In a phase III International Liver Tumor Strategy Group trial (SIOPEL 6) reported in The New England Journal of Medicine, Brock et al found that sodium thiosulfate reduced cisplatin-induced hearing loss in pediatric patients with standard-risk hepatoblastoma.

Study Details

The trial enrolled a total of 116 children aged > 1 month to < 18 years from 52 centers in 12 countries between 2007 and 2014. Of these, 109 eligible patients constituted the intention-to-treat population and 101 could be evaluated for the primary endpoint. Standard-risk hepatoblastoma was defined as ≤ 3 involved liver sectors, no metastatic disease, and alpha-fetoprotein level of > 100 ng/mL. Patints were randomized to receive cisplatin alone at 80 mg/m2 over 6 hours (n = 52; median age = 13.4 years) or cisplatin plus sodium thiosulfate at 20 g/m2 given intravenously for 15 minutes 6 hours after discontinuation of cisplatin (n = 57; median age = 12.8 years) for four preoperative and two postoperative courses.

The primary endpoint was the absolute hearing threshold measured by pure-tone audiometry at a minimum age of 3.5 years. Hearing loss was assessed by Brock grade, with higher grades on a scale of 0 to 4 indicating greater hearing loss. The main secondary endpoints were overall survival and event-free survival at 3 years.

Audiometry and Survival Outcomes

Final audiometry was performed at a median of 3 years after randomization. Hearing loss of grade ≥ 1 occurred in 18 (33%) of 55 children in the cisplatin-sodium thiosulfate group vs 29 (63%) of 46 in the cisplatin-alone group (relative risk = 0.52, P = .002).

At a median of 52 months of follow-up, the 3-year rates of event-free survival were 82% in the cisplatin-sodium thiosulfate group vs 79% in the cisplatin group, and 3-year rates of overall survival were 98% vs 92%.

Adverse Events

Grade 3 or 4 adverse events occurring in ≥ 10% of the cisplatin-sodium thiosulfate group or the cisplatin group were grade 3 infection (23% vs 31%), anemia (20% vs 15%), neutropenia (17% vs 12%), grade 3 febrile neutropenia (14% vs 19%), and elevated liver enzymes (7% vs 12%). 

The investigators concluded, “The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival.”

The study was funded by Cancer Research UK and others.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.